Market closedNon-fractional

REGENXBIO/RGNX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About REGENXBIO

Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.

Ticker

RGNX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Rockville, United States

Employees

344

REGENXBIO Metrics

BasicAdvanced
$533M
Market cap
-
P/E ratio
-$5.87
EPS
1.34
Beta
-
Dividend rate
$533M
1.34
3.589
3.218
31.967
43.66
-42.77%
-23.60%
-60.80%
5.527
1.37
1.37
-2.413
-20.90%
-6.03%
-17.74%
23.00%

What the Analysts think about REGENXBIO

Analyst Ratings

Majority rating from 11 analysts.
Buy

REGENXBIO Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-405.76% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$16M
-29.73%
Net income
-$63M
0.80%
Profit margin
-405.76%
43.44%

REGENXBIO Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 9.61%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$1.66
-$1.41
-$1.43
-$1.38
-
Expected
-$1.39
-$1.52
-$1.27
-$1.26
-$1.29
Surprise
19.86%
-7.10%
12.55%
9.61%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for REGENXBIO stock?

REGENXBIO (RGNX) has a market cap of $533M as of July 05, 2024.

What is the P/E ratio for REGENXBIO stock?

The price to earnings (P/E) ratio for REGENXBIO (RGNX) stock is 0 as of July 05, 2024.

Does REGENXBIO stock pay dividends?

No, REGENXBIO (RGNX) stock does not pay dividends to its shareholders as of July 05, 2024.

When is the next REGENXBIO dividend payment date?

REGENXBIO (RGNX) stock does not pay dividends to its shareholders.

What is the beta indicator for REGENXBIO?

REGENXBIO (RGNX) has a beta rating of 1.34. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell REGENXBIO stock

Buy or sell REGENXBIO stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing